Welcome to our dedicated page for Puma Biotechnology news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on Puma Biotechnology stock.
Puma Biotechnology, Inc. (NASDAQ: PBYI) is a biopharmaceutical company focused on developing and commercializing products to enhance cancer care, and its news flow reflects this oncology focus. The company’s primary commercial product is NERLYNX (neratinib) tablets, an oral kinase inhibitor approved by the U.S. Food and Drug Administration for specific early-stage and metastatic HER2-positive breast cancer indications. NERLYNX also holds marketing authorization from the European Commission for defined early-stage hormone receptor-positive, HER2-overexpressed or amplified breast cancer settings.
News about PBYI often highlights commercial performance and financial results related to NERLYNX, including product revenue, royalty revenue, and updates on profitability and cash flow. Puma’s press releases also cover corporate developments such as inclusion in the Nasdaq Biotechnology Index, which tracks qualifying biotechnology and pharmaceutical companies listed on Nasdaq.
Another key news theme is clinical progress with alisertib, a selective, orally administered inhibitor of aurora kinase A that Puma is developing under an exclusive license. The company has launched Phase II ALISCA trials, including ALISCA-Lung1 in extensive-stage small cell lung cancer and ALISCA-Breast1 in HER2-negative, hormone receptor-positive metastatic breast cancer. Updates on these studies, including interim data and trial milestones, feature prominently in Puma’s communications.
Investors following PBYI news can also expect announcements about equity inducement awards under Puma’s 2017 Employment Inducement Incentive Award Plan, conference call schedules for quarterly results, and presentations at investor conferences. This news page aggregates those releases so readers can track how regulatory decisions, clinical trial developments, commercial trends, and corporate actions may relate to Puma Biotechnology’s stock and oncology pipeline over time.
Puma Biotechnology (NASDAQ: PBYI) announced that on October 1, 2025 its Compensation Committee approved an inducement restricted stock unit (RSU) award of 9,375 shares to one new non-executive employee under the 2017 Employment Inducement Incentive Award Plan. The RSU award vests over a three-year schedule: one-third on the first anniversary of the vesting commencement date (October 1, 2025) and one-sixth on each subsequent six-month anniversary, subject to continued service. The grant was made pursuant to Nasdaq Listing Rule 5635(c)(4) as an inducement to employment.
Puma Biotechnology (Nasdaq: PBYI) announced the approval of inducement restricted stock unit awards for four new non-executive employees. The Compensation Committee approved grants totaling 25,750 shares of Puma common stock on September 2, 2025, under the company's 2017 Employment Inducement Incentive Award Plan.
The restricted stock units will vest over three years, with one-third vesting on the first anniversary of the August 1 and September 1, 2025 commencement dates, followed by one-sixth vesting every six months thereafter, contingent on continued employment. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Puma Biotechnology (NASDAQ: PBYI) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. Alan H. Auerbach, the company's Chairman, CEO, President and Founder, will present a company overview on September 8, 2025 at 1:00 p.m. EDT at the Lotte New York Palace Hotel.
The presentation will be accessible through a live webcast on Puma's website and will remain available for 30 days following the event.
Puma Biotechnology (NASDAQ: PBYI) announced the approval of inducement restricted stock unit awards for three new non-executive employees. The Compensation Committee approved grants totaling 27,875 shares of Puma common stock on August 5, 2025.
The awards, granted under Puma's 2017 Employment Inducement Incentive Award Plan, will vest over three years starting August 1, 2025. The vesting schedule includes one-third of shares vesting after the first year, followed by one-sixth of shares vesting every six months thereafter, contingent on continued employment.
Puma Biotechnology (NASDAQ: PBYI) reported strong Q2 2025 financial results, with product revenue reaching $49.2 million, up from $44.4 million in Q2 2024. The company achieved net income of $5.9 million ($0.12 per share), compared to a net loss of $4.5 million in Q2 2024. Total revenue was $52.4 million, including $3.2 million in royalty revenue.
The company's flagship product NERLYNX® drove year-over-year growth, while operating costs decreased to $45.8 million from $49.3 million. Puma maintains its full-year 2025 guidance of $212-$222 million in total revenue and expects net income between $23-$28 million. The company also reported progress in clinical trials for alisertib in breast and lung cancer, with interim data expected in Q4 2025.
[ "Net income of $5.9 million in Q2 2025, compared to $4.5 million loss in Q2 2024", "Product revenue increased 10.8% to $49.2 million year-over-year", "Operating costs decreased by 7.1% to $45.8 million", "Strong cash position of $96.0 million as of June 30, 2025", "Net cash from operations increased to $14.1 million from $1.0 million in Q2 2024" ]Puma Biotechnology (NASDAQ: PBYI) has announced it will host a conference call to discuss its second quarter 2025 financial results on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET.
Investors can access the call via phone using the dial-in numbers 1-877-709-8150 (domestic) or 1-201-689-8354 (international). A live webcast and presentation slides will be available on the company's investor relations website. The call recording will be archived on Puma's website for 90 days.
Puma Biotechnology (NASDAQ: PBYI) announced the approval of inducement restricted stock unit awards for two new non-executive employees. The Compensation Committee approved grants totaling 7,000 shares of Puma common stock on July 1, 2025, under the company's 2017 Employment Inducement Incentive Award Plan.
The restricted stock units will vest over three years, with one-third vesting on July 1, 2026, and one-sixth vesting every six months thereafter, contingent on continued employment. These awards were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) has granted inducement restricted stock unit awards to two new non-executive employees. The awards, approved by the Compensation Committee on May 5, 2025, cover 12,875 shares of Puma common stock. These equity awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan.
The restricted stock units will vest over three years, with one-third vesting on the first anniversary of the vesting commencement dates (April 1, 2025 and May 1, 2025), followed by one-sixth vesting every six months thereafter, contingent on continued employment. The awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for the new employees joining Puma.